The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on ...

Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 9 unusual trades. Delving into ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of losses.